The popularity of copyright’s blockbuster initially sparked a surge for the drug industry, nevertheless recent developments present a complicated scenario for those considering a stake. Off-patent competitors are reducing revenue, and continued legal battles add more risk to the situation. While certain companies could still see gains from relate